welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Health

Health

Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

74% Informative

Amgen Inc. (NASDAQ: AMGN ) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers.

Gastric cancer is the fifth leading cause of cancer-related death globally, with nearly 1 million new cases and over 650,000 deaths each year .

The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint.

VR Score

65

Informative language

60

Neutral language

27

Article tone

formal

Language

English

Language complexity

65

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links